Who are Fluorouracil implant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, Fluorouracil Injection, Anlotinib plus Pemetrexed, 5-Fluorouracile.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fluorouracil-implant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Fluorouracil implant — Competitive Intelligence Brief

Fluorouracil implant (Fluorouracil implant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite chemotherapy agent. Area: Oncology.

phase 3 Antimetabolite chemotherapy agent Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Fluorouracil implant (Fluorouracil implant) — Austrian Breast & Colorectal Cancer Study Group. Fluorouracil implant delivers the chemotherapy agent 5-fluorouracil directly to tumor tissue to inhibit thymidylate synthase and disrupt DNA synthesis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fluorouracil implant TARGET	Fluorouracil implant	Austrian Breast & Colorectal Cancer Study Group	phase 3	Antimetabolite chemotherapy agent	Thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
Fluorouracil Injection	Fluorouracil Injection	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	marketed	Antimetabolite	Thymidylate synthase
Anlotinib plus Pemetrexed	Anlotinib plus Pemetrexed	Henan Provincial People's Hospital	marketed	Multi-target tyrosine kinase inhibitor plus antifolate antimetabolite	VEGFR, FGFR, RET, c-Kit (anlotinib); thymidylate synthase, DHFR, GARFT (pemetrexed)
5-Fluorouracile	5-Fluorouracile	Groupe Oncologie Radiotherapie Tete et Cou	marketed	Antimetabolite; pyrimidine analog	Thymidylate synthase; RNA and DNA incorporation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite chemotherapy agent class)

Austrian Breast & Colorectal Cancer Study Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluorouracil implant — Competitive Intelligence Brief. https://druglandscape.com/ci/fluorouracil-implant. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab